On May 29, 2025, the Pharmaceutical company Regeneron had agreed to buy 23andMe.com, the leading personal genomics and biotechnology company to resolve the company’s bankruptcy.
On June 16, 2025 former 23andMe CEO Anne Wojcicki made a $305 million bid for the company. Wojcicki had previously tried to buy the company, but was unsucessful. This success was with the backing of her non-profit TTAM Research Institute and a Fortune 500 company.
Regeneron has stated that they are willing to make a new bid. The Guardian reports that "TTAM said on Friday it would uphold 23andMe’s existing privacy policies and comply with all applicable data protection laws."